Last update 26 Dec 2024

IBR900

Overview

Basic Info

Drug Type
Natural Killer Cell Therapies
Synonyms
IBR 900, IBR-900, IBR900
Target-
Mechanism
Natural killer cell replacements
Therapeutic Areas
NeoplasmsDigestive System DisordersImmune System Diseases+ [2]
Active Indication
Primary Malignant Liver NeoplasmB-Cell LymphomaSystemic Lupus Erythematosus
Inactive Indication-
Originator Organization
Yingbairui (Hangzhou) Biomedical Co., Ltd.Yingbairui (Hangzhou) Biomedical Co., Ltd.
Active Organization
Yingbairui (Hangzhou) Biomedical Co., Ltd.Yingbairui (Hangzhou) Biomedical Co., Ltd.
Inactive Organization-
Drug Highest PhaseEarly Phase 1
First Approval Date-
Regulation-
Login to view timeline

Related

2
Clinical Trials associated with IBR900
NCT05411757 / Not yet recruitingEarly Phase 1IIT
A Single-Arm, Open-Label Clinical Trial to Evaluate the Safety, Tolerability and Efficacy of IBR900 Cell Injection Combined With Lenvatinib or Bevacizumab in the Treatment of Subjects With Advanced Primary Liver Cancer
NCT05271279 / TerminatedEarly Phase 1
A Single-Arm, Open-Label, Investigator-Initiated Clinical Trial to Evaluate the Safety, Tolerability and Efficacy of Oncolytic Virus Injection (OVV-01) in Combination With IBR900 Cell Injection in Patients With Advanced Malignant Tumors
100 Clinical Results associated with IBR900
Login to view more data
100 Translational Medicine associated with IBR900
Login to view more data
100 Patents (Medical) associated with IBR900
Login to view more data
100 Deals associated with IBR900
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Primary Malignant Liver NeoplasmPhase 1-
Yingbairui (Hangzhou) Biomedical Co., Ltd.Yingbairui (Hangzhou) Biomedical Co., Ltd.
30 Jun 2022
B-Cell LymphomaIND Approval
CN
Yingbairui (Hangzhou) Biomedical Co., Ltd.Yingbairui (Hangzhou) Biomedical Co., Ltd.
25 Sep 2024
Systemic Lupus ErythematosusIND Application
CN
Yingbairui (Hangzhou) Biomedical Co., Ltd.Yingbairui (Hangzhou) Biomedical Co., Ltd.
06 Nov 2024
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free